As with most drug pricing battles, patients yet again are caught in the crossfire.
You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.
Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.
Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.
Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.
Seifert said feedback from clients has been positive.
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.
The healthcare marketing group made another major acquisition in the country last month.
Omnicom's healthcare revenue was up 2.7% in Q1
J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.
Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.
The firm hired five senior staff in the past month.
Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.
As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.
Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.
John Tylee examines how a man who never ran an agency rose to become such a dominant force.
Martin Sorrell has stood down as chief executive of WPP, the company has announced.